OHR Pharmaceutical   Report issue

For profit Phase 2 Phase 3
Founded: New York NY United States (2008)
Status: Defunct (2021)

Organization Overview

First Clinical Trial
2010
NCT01206335
First Marketed Drug
None
First NDA Approval
None
Last Known Activity
2016

Timeline

NOW
  • Now

Alternative names

Ohr Pharmaceutical Inc.

Active Ingredients

Drugs in Phase 3 Trials (2)

ranibizumab (lucentis) (3 trials)

squalamine (5 trials)

Drugs in Phase 2 Trials (1)

avr118 (1 trial)

Indications

Experimental Indications (Clinical Trials, Phases 1-4)


 

Anorexia (Phase 2)

Cachexia (Phase 2)

Diabetic Retinopathy (Phase 2)

Edema (Phase 2)

Macular Degeneration (Phase 3)

Macular Edema (Phase 2)

Retinal Vein Occlusion (Phase 2)

Wasting Syndrome (Phase 2)

Overview

  • Highest Phase: Phase 3
  • # of Trials: 6
  • # of Trial APIs: 3